frontiers in Pharmacology

CORRECTION
published: 09 October 2018
doi: 10.3389/fphar.2018.01128

Corrigendum: Ulinastatin Inhibits Osteoclastogenesis and Suppresses Ovariectomy-Induced Bone Loss by Downregulating uPAR

Jun-ming Huang†, Ran-yue Ren†, Yuan Bao, Jia-chao Guo, Wei Xiang, Xing-zhi Jing, Jia Shi, Guo-xiang Zhang, Long Li, Yong Tian, Hao Kang and Feng-jin Guo**

Department of Orthopedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Keywords: ulinastatin, uPAR, osteoclast, MAPKs, NF-kB, RANKL, osteoporosis

OPEN ACCESS

Edited and reviewed by:
Wolff Mayer Kirsch, Loma Linda University Medical Center (LLUMC), United States

****Correspondence:***
Hao Kang
kanghao100@vip.sina.com
Feng-jin Guo
fguo@tjh.tjmu.edu.cn

†These authors have contributed equally to this work

Specialty section:
This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology

Received: *07 September 2018*
Accepted: *14 September 2018*
Published: *09 October 2018*

Citation:
Huang J, Ren R, Bao Y, Guo J, Xiang W, Jing X, Shi J, Zhang G, Li L, Tian Y, Kang H and Guo F (2018) Corrigendum: Ulinastatin Inhibits Osteoclastogenesis and Suppresses Ovariectomy-Induced Bone Loss by Downregulating uPAR. Front. Pharmacol. 9:1128. doi: 10.3389/fphar.2018.01128

A Corrigendum on

Ulinastatin Inhibits Osteoclastogenesis and Suppresses Ovariectomy-Induced Bone Loss by Downregulating uPAR

by Huang, J., Ren, R., Bao, Y., Guo, J., Xiang, W., Jing, X., et al. (2018). Front. Pharmacol. 9:1016. doi: 10.3389/fphar.2018.01016

In the original article, there was a mistake in **Figure 1** as published. The images used for the group of OVX+U were from a different study. The corrected **Figure 1** appears below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

The original article has been updated.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.



FIGURE 1 | Ulinastatin inhibits bone loss induced by OVX. **(A)** μ-CT images of the trabecular bone of distal femoral metaphysis from the SHAM, OVX, and OVX + ulinastatin groups. **(B)** The trabecular structural parameters of the distal femur: trabecular bone volume/tissue volume (BV/TV), trabecular number (Tb.N), trabecular thickness (Tb.Th), and trabecular separation (Tb.Sp). Data are presented as means ± *SD*. $n = 10$ and $^*P < 0.05$.